Nagi Bioscience SA

Nagi Bioscience SA

Private
Saint-SulpiceHealthcare & Life Scienceshttps://nagibio.ch

Last Round

Series A

Sep 28, 2023

Total Funding Raised

$18.4M

Momentum Score

50 /100

Company Overview

Nagi Bioscience SA is a biotechnology company that develops and provides organism-on-chip technology for automated biological testing as an alternative to animal testing.

Sector

Healthcare & Life Sciences

Verticals

Biotech Equipment, Drug Discovery, Biotechnology, Medical AI

Business Model

B2B

Customer Profile

Hardware Sales, Services & Consulting, Hardware + Subscription, Government Contracts

AI Layer

Application

Keywords

organism-on-chipC. elegans modelhigh-throughput screeningHTSanimal testing alternativelab automationmicrofluidicscontract research organizationCROnew alternative methodsNAMsphenotypic screeningAI-driven analysisdrug discovery platformtoxicology testingtox screening3R principleslongevity researchhigh-content analysisin vivo testing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nagi Bioscience SA Comps

Public and private peers based on sector, stage, and business model.

CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Nagi Bioscience SA Funding Rounds

Historical fundraising activity

RoundDateAmount RaisedValuationInvestorsSources
Series ASep 28, 2023
GrantMar 21, 2022
SeedDec 20, 2019
AcceleratorJan 31, 2019
GrantJul 4, 2018

Key People

Founding team and executive leadership

Matteo Cornaglia

CEO Founder

Founding Team

Nagi Bioscience SA Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Apr 9, 2025

    Rhino Bio Inc. will distribute analytical systems in South Korea.

Nagi Bioscience SA Filings

SEC and related filings with document metadata.

TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Nagi Bioscience SA Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Nagi Bioscience SA's valuation, stock price, and market status.

Firmographic Details

HeadquartersSaint-Sulpice
Employee Range53
Year Founded2019
Last FundingSep 28, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.







Disclaimer All investments involve risk, including the risk of loss of principal. You should carefully consider your investment objectives, risks, transaction costs and other expenses before deciding to invest in options, swaps or other investments.This does not constitute an offer by Caplight Technologies, Inc. to sell, or a solicitation of an offer to buy, any securities and may not be used or relied upon in connection with any offer or sale of securities. An offer or solicitation can be made only through the delivery of final offering document(s) and purchase agreement(s), and will be subject to the terms and conditions and risks delivered in such documents. Any securities offered are offered through Caplight Markets LLC, member FINRA/SIPC.